Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Urgent action to tackle antimicrobial resistance must take account of all the scientific opportunities available, find new resources to support academia and emphasize the importance of innovation to policy-makers and to the general public.
The Innovative Medicines Initiative's DRIVE-AB project joins the fray of task forces working to reinvigorate interest in antibiotics by developing reimbursement models that delink revenue from sales volume.
Recent results have cast doubt over how effective a breakthrough class of cystic fibrosis drugs can be in patients with the most common form of the disease.
Story Landis, ex-Director of the US National Institute of Neurological Disorders and Stroke, discusses how she has worked to address a crisis of basic research funding at the Institute.
Current treatments for cystic fibrosis are largely symptomatic, but the first disease-modifying drug has recently been approved and others are progressing. This article examines the multitude of agents in the clinical pipeline and their potential market impact in the next 5 years.
Caloric restriction can promote health and extend the lifespan of model organisms, and diverse classes of compounds that mimic the biochemical and functional effects of caloric restriction have attracted considerable interest as potential pharmacotherapies for diseases such as diabetes and obesity. Kroemer, Madeo and colleagues propose a unifying definition of caloric restriction mimetics as agents that induce autophagy by promoting protein deacetylation, which could have implications for their development as drugs.
Sepsis is a potentially fatal systemic disease that is caused by microbial infection. Despite numerous clinical trials, no specific therapeutic agent has yet been approved for this indication. Here, Fink and Warren consider potential reasons for such failures and suggest possible strategies to overcome ongoing challenges, such as improving clinical trial design.
The therapeutic potential ofin vitro-transcribed mRNA (IVT mRNA) extends from prophylactic and therapeutic vaccines to applications such as protein replacement and genome engineering. In this Review, the authors describe the recent developments in the IVT mRNA field, discuss the class-specific challenges with regards to translating IVT mRNA into a biopharmaceutical, and provide an overview of IVT mRNA drugs in development for different indications.
